Selecta Biosciences Presents New Preclinical Data from its Gene Therapy Program at 2019 ESGCT Annual Congress
23 oct. 2019 10h48 HE
|
Selecta Biosciences, Inc.
Highlights the ability to prevent formation of vector-induced neutralizing antibodies (Nabs) and enable re-administration of AAV vectors in combination with Selecta’s ImmTOR (SVP-Rapamycin)...
Selecta Biosciences to Participate in Two Investor Conferences in October
25 sept. 2019 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Appoints Brad Dahms as Chief Financial Officer
04 sept. 2019 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences to Present at the Janney Healthcare Conference
03 sept. 2019 08h07 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Reports Second Quarter 2019 Financial Results and Provides Corporate Update
08 août 2019 08h00 HE
|
Selecta Biosciences, Inc.
- New strategic partnership with gene therapy leader, AskBio, to jointly develop next-generation AAV-based gene therapies to address the unmet medical need for repeat dosing in patients with rare and...
Selecta Biosciences Combines ImmTOR™ Platform with AskBio’s Industry-Leading Gene Therapy Platform in Strategic Partnership
07 août 2019 07h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass. and RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB) and Asklepios BioPharmaceutical, Inc. (AskBio), today announced a...
Selecta Biosciences Announces Date of Second Quarter 2019 Financial Results Conference Call
01 août 2019 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences to Present at Canaccord Genuity’s 39th Annual Growth Conference on August 7, 2019
31 juil. 2019 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Appoints Alison Schecter, M.D., as Chief Medical Officer
15 juil. 2019 08h00 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., July 15, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
Selecta Biosciences Announces Appointment of Scott D. Myers to Board of Directors
20 juin 2019 16h05 HE
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., June 20, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...